CBD & Hemp
Data-driven coverage of CBD innovation, hemp policy, and wellness applications.
CBD & Hemp · page 3
- Cultivation
India Issues First Cannabis Research Grant That Could Help Open Up Market
For the first time in over 5 decades, the Indian government has granted public funding to a cannabis research project, with ramifications which will determine ‘whether India can build a credible pharmaceutical industry’ around cannabis.
- Hemp Industry
UK Hemp Industry Has Everything It Needs Except the Law
The UK’s industrial hemp sector, and its potential, have been raised in Parliament nearly as many times in the first three months of 2026 as the entirety of 2025.
- Hemp Industry
House Agriculture Committee Advances Farm Bill With No Relief for Hemp Industry
The US House Agriculture Committee has voted to advance the 2026 farm bill without adopting any provisions to delay or repeal the incoming ban on intoxicating hemp.
- CBD Market
Clinical Evidence vs. Food Law: Europe’s CBD Dilemma
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety Authority (EFSA) terminating four novel food applications, just days after announcing incredibly restrictive new safety limits.
- CBD Market
UK CBD: A Regulator Finding Its Stride, A Sector Holding Its Breath
The UK’s CBD novel foods programme enters 2026 with its autumn ministerial approval target still nominally intact, but facing increasing pressure on multiple fronts.
- CBD Market
US Hemp Industry in Limbo as FDA Deadline for Cannabinoid Definitions Arrives
The Food and Drug Administration’s (FDA) 90-day deadline to clarify which cannabinoids will be banned under the incoming, controversial intoxicating hemp ban falls today.
- CBD Market
UK CBD Approvals Face Autumn 2026 Crunch as Industry Proposes Framework Overhaul
The UK’s first-ever CBD product authorisations, originally expected to be completed by Autumn 2026, could now face another setback as Food Standards Scotland (FSS) insists on holding its own consultation.
- Clinical Research
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant shift in US drug policy in over half a century.
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- CBD Market
CBD Company Founder Wins £137k Unfair Dismissal Award Amid Cannim Group Collapse
Last month, international cannabis operator Cannim collapsed, calling in administrators to sift through the company’s remaining assets and attempt to find tens of millions of dollars to satisfy its increasingly frustrated creditors.
- Hemp Industry
Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
- CBD Market
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to authorise insurance coverage for CBD products under certain Medicare programs, even as the same products face an existential threat from recently passed federal legislation.










